Results 11 to 20 of about 16,276 (198)
Frontiers in Cardiovascular Medicine, 2023 BackgroundCertain genetic and non-genetic factors may cause damaged platelet inhibition by clopidogrel. We aimed to determine the effect of cytochrome P4502C19 (CYP2C19) polymorphism, along with other clinical factors, on the platelet response to ...
Yijun Mo +4 more
doaj +1 more source
Journal of Pharmaceutical Health Care and Sciences, 2020 Background Repaglinide is widely prescribed to reduce postprandial hyperglycemia and elevated glycated hemoglobin (HbA1c) levels associated with type 2 diabetes, and clopidogrel is a thienopyridine antiplatelet agent and widely used in cardiovascular and
Yuuki Akagi +9 more
doaj +1 more source
European Journal of Medical Research, 2010 Background Dual therapy with aspirin and clopidogrel increases the risk of gastrointestinal bleeding. Therefore, co-therapy with a proton pump inhibitor (PPI) is recommended by most guidelines.
Kenngott S +6 more
doaj +1 more source
Atorvastatin and Clopidogrel [PDF]
Circulation, 2003 To the Editor: I would like to comment on the recent editorial by Serebruany et al1 in which the study results by Lau et al2 are discussed. It is argued that these results, which are suggestive of a clinically relevant interaction between clopidogrel and atorvastatin, are in conflict with those published previously by Serebruany et al.3 According to ...
openaire +2 more sources
Clopidogrel resistance: The way forward
Indian Heart Journal, 2014 Clopidogrel, a second generation thienopyridine has been the mainstay of ACS (Acute Coronary Syndrome) treatment for more than a decade. Clopidogrel Resistance has been associated with increased mortality in ACS patients with an increase in number of ...
Shuvanan Ray
doaj +1 more source
A study on the impact of CYP2C19 genotype and platelet reactivity assay on patients undergoing PCI
Indian Heart Journal, 2015 Background: A thorough understanding of the patient's genotype and their functional response to a medication is necessary for improving event free survival.
P.C. Rath +9 more
doaj +1 more source
Рациональная фармакотерапия в кардиологии, 2015 Aim. To study prevalence of resistance to acetylsalicylic acid, clopidogrel and dual resistance in percutaneous coronary intervention (PCI), to identify clinical risk factors of resistance development, to study effects of concomitant therapy on ...
V. A. Sulimov, E. V. Moroz
doaj +3 more sources
Effects of clopidogrel on mortality, cardiovascular and bleeding outcomes in patients with chronic kidney disease - data from Taiwan acute coronary syndrome full spectrum registry. [PDF]
PLoS ONE, 2013 BACKGROUND: The efficacy of clopidogrel is inconclusive in the chronic kidney disease (CKD) population with acute coronary syndrome (ACS). Furthermore, CKD patients are prone to bleeding with antiplatelet therapy.
Tsung-Hsien Lin +9 more
doaj +1 more source
Scientific Reports, 2021 Clopidogrel is converted to its active metabolite by cytochrome P450 isoenzymes and irreversibly inhibits platelet activation by antagonizing the adenosine-diphosphate (ADP) receptor.
Yu Ueda +8 more
doaj +1 more source
Periodontitis and atherosclerotic cardiovascular disease: A critical appraisal
Periodontology 2000, EarlyView., 2023 Abstract In spite of intensive research efforts driving spectacular advances in terms of prevention and treatments, cardiovascular diseases (CVDs) remain a leading health burden, accounting for 32% of all deaths (World Health Organization. “Cardiovascular Diseases (CVDs).” WHO, February 1, 2017, https://www.who.int/news‐room/fact‐sheets/detail ...
Maria Clotilde Carra +3 more
wiley +1 more source